Dr. Hanns Lochmüller Receives the Dr. George Karpati Award for Researcher of the Year

Published: 10 December 2021

Dr. Hanns Lochmüller is the recipient of Muscular Dystrophy Canada‘s Dr. George Karpati Award for Researcher of the Year! This prestigious award is presented annually to an exemplary neuromuscular clinician or researcher who has made a significant contribution to neuromuscular research, or the advancement of care of people with neuromuscular disorders. 

Dr. Lochmuller is a neurologist and clinical academic specializing in genetic neuromuscular disorders and rare disease in Ottawa, and supports the neuromuscular community in many ways: He is the lead Principal Investigator of the Neuromuscular Disease Network for Canada (NMD4C); He is an active member of MDC’s Medical and Scientific Advisory Committee (MSAC); He reviews research grants, speaks at various webinars, contributes to publications (over 30 in 2021 alone!), serves as a role model for early career clinicians and scientists, as well as serving as an academic lead on MDC’s Economic Cost of Living Study.

Dr. Lochmuller is a champion for the patient community and is strongly committed to bringing patients and patient organizations into equal partnerships. He has been instrumental in ensuring individuals impacted by NMDs and their family members are at the center of advances in the neuromuscular community in Canada and abroad.

Read more about Dr. Lochmüller’s accomplishments and research here.

Hanns_KarpatiAward_MDClogo

Read next...

award winners

Celebrating Lab Members’ Recent Research Awards

We are thrilled to celebrate Kelly Ho for receiving first place for her poster presentation at this year’s American Society for Pharmacology and Experimental Therapeutics...
New publication - RTD (2)

Meet The Lochmüller Lab’s Newest Members!

Our research team is growing! We are excited to introduce three new members who have recently joined the Lochmüller lab and several students who will...
McMillan smart study (1)

New Clinical Study Examines Safety and Efficacy of IV Onasemnogene Abeparvovec in Broad SMA Cohort

Pediatric neurologist Dr Hugh McMillan publishes clinical study examining the safety and efficacy of IV onasemnogene abeparvovec in the broadest cohort of SMA patients to...
Text reading: Solve-RD publication: Solve-RD flagship publication: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. Photos of Dr Kiran Polavarapu, Dr Rachel Thompson, Dr Hanns Lochmüller.

Solve-RD flagship publication in Nature Medicine: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

Patients and families with rare disorders often remain without a genetic diagnosis despite modern advances in diagnostic testing. Due to the rarity and global distribution...
New publication: Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis . Author's photos on the right, diagram from paper underneath title.

New Lab Publication Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis

Rhabdomyolysis is an acute failure of cellular homeostasis characterized by acute skeletal muscle damage triggered by trauma, infection, drugs, or strenuous exercise. Recurrent rhabdomyolysis is...
New lab publication on riboflavin transporter deficiency model

New Publication: Development of a riboflavin-responsive model of riboflavin transporter deficiency in zebrafish

Riboflavin transporter deficiency (RTD) is a rare genetic disorder in children, characterised by progressive sensorimotor and cranial neuronopathy caused by mutations in riboflavin transporter protein-encoding...